Since poor circadian synchrony and cognitive dysfunction have been linked to affective disorders, antidepressants that target key 5-HT (serotonin) receptor subtypes involved in circadian rhythm and cognitive regulation may have therapeutic utility. Vortioxetine is a multimodal antidepressant that inhibits 5-HT 1D , 5-HT 3 , 5-HT 7 receptor activity, 5-HT reuptake, and enhances the activity of 5-HT 1A and 5-HT 1B receptors. In this study, we investigated the effects of vortioxetine on the period length of PER2::LUC expression, circadian behavior, and episodic memory, using tissue explants from genetically modified PER2::LUC mice, locomotor activity rhythm monitoring, and the object recognition test, respectively. Incubation of tissue explants from the suprachiasmatic nucleus of PER2::LUC mice with 0.1 mM vortioxetine increased the period length of PER2 bioluminescence. Monitoring of daily wheelrunning activity of SpragueeDawley rats treated with vortioxetine (10 mg/kg, s.c.), alone or in combination with the 5-HT 1A receptor agonist flesinoxan (2.5 mg/kg, s.c.) or the 5-HT 7 receptor antagonist SB269970 (30 mg/kg, s.c.), just prior to activity onset revealed significant delays in wheel-running behavior. The increase in circadian period length and the phase delay produced by vortioxetine were abolished in the presence of the 5-HT 7 receptor partial agonist AS19. Finally, in the object recognition test, vortioxetine (10 mg/kg, i.p.) increased the time spent exploring the novel object during the retention test and this effect was prevented by AS19 (5 mg/kg, i.p.). In conclusion, the present study shows that vortioxetine, partly via its 5-HT 7 receptor antagonism, induced a significant effect on circadian rhythm and presented promnesic properties in rodents.
Introduction
The serotonergic neurotransmitter system comprises an extensive and complex network within the central nervous system (reviewed by (Artigas, 2013) ). Numerous physiological functions are influenced by serotonin (5-HT), e.g., aggression/impulse control, anxiety/affect, appetitive/satiety, circadian rhythms/sleep, cognitive function, endocrine regulation, gastrointestinal functions, motor activity, pain, reproduction functions, sensory functions (Murphy et al., 1998) . The brain's serotonergic neurons originate mainly from the dorsal and median raphe nuclei of the brainstem and are extensively arborized, thereby innervating most of the brain. A total of fifteen 5-HT receptor subtypes mediate serotonergic neurotransmission; some of them are located on 5-HT neurons regulating serotonergic neurotransmission, while others are involved in controlling other neurotransmitter systems, such as the glutamatergic, noradrenergic and dopaminergic. The 5-HT 7 receptor was first cloned in 1993 and its physiological roles have mainly been related to regulation of circadian rhythms, sleep and mood, but also to the regulation of cognitive function (Cowen and Sherwood, 2013; Hedlund, 2009; Hedlund and Sutcliffe, 2004) .
Vortioxetine (Lu AA21004; 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is an antidepressant with a multimodal mechanism of action approved for the treatment of major depressive disorders (Adell, 2010; Alvarez et al., 2012) . In in vitro studies in cell lines expressing cloned human 5-HT receptors and the 5-HT transporter (SERT), vortioxetine is a 5-HT 3A (Ki ¼ 3.7 nM), 5-HT 7 (Ki ¼ 19 nM) and 5-HT 1D (Ki ¼ 54 nM) receptor antagonist, 5-HT 1B receptor partial agonist (Ki ¼ 33 nM; IA 55%), 5-HT 1A receptor agonist (Ki ¼ 15 nM) and inhibitor of the 5-HT transporter (SERT; Ki ¼ 1.6 nM) (Bang-Andersen et al., 2011; Westrich et al., 2012) . In preclinical rodent studies, vortioxetine showed the potential to improve cognitive function . Furthermore, in two clinical studies vortioxetine has been shown to be superior to placebo in pre-defined cognitive outcome measures in patients with major depressive disorder (Katona et al., 2012; McIntyre et al., 2013) .
We have previously shown that concomitant inhibition of 5-HT reuptake and 5-HT 7 receptors resulted in period lengthening of PERIOD2::LUCIFERASE (PER2::LUC) bioluminescence in an in vitro preparation of the suprachiasmatic nucleus (SCN) of the hypothalamus from knock-in mice, and in a phase delay in the circadian rhythm of freely behaving rats (Westrich et al., 2013) . In the present study, we investigated the effect of vortioxetine on the period length of PER2::LUC expression and circadian behavior. Since vortioxetine has markedly lower affinity for 5-HT 1A and 5-HT 7 receptors in rodents than in humans (Bang-Andersen et al., 2011; Mork et al., 2012) we also explored the effects of vortioxetine in combination with the 5-HT 1A receptor agonist flesinoxan, and the 5-HT 7 receptor antagonist SB269970. Furthermore, we have previously shown that vortioxetine improved recognition memory in a time delay object recognition test in rats . Here we assess a putative role of vortioxetine's 5-HT 7 receptor antagonism with respect to its action on episodic memory using the object recognition test.
Methods

Animals
Three-to six-month-old male homozygous PER2::LUC knock-in mice (Yoo et al., 2004) purchased from Jackson Laboratory (Bar Harbor, ME) were housed in a 12 h:12 h light:dark (12:12 LD) cycle for at least 2 weeks prior to dissection and tissue collection. Two-month-old SpragueeDawley male rats purchased from Charles River Laboratories (Wilmington, MA) were housed individually with free access to running wheels (model 80820, Lafayette Instruments, Lafayette, IA) for the duration of the experiment. All animals were maintained under controlled environmental conditions (22 ± 2 C; lights on at 06:00 to 18:00 h) with food and water available ad libitum. All animal protocols were approved by the Lundbeck Research USA, Inc. Institutional Animal Care and Use Committee.
The experiments involving the object recognition test were carried out with male SpragueeDawley OFA rats (Charles River, FRANCE) weighing 250e310 g at the time of the experiment. The animals were housed four per cage under standard laboratory conditions; 12 h:12 h light:dark cycle with food and water available ad libitum. Experiments were performed in compliance with the European Communities Council Directive 86/609 ECC for the care and use of laboratory animals and with the approval of the Regional Animal Care Committees (University Lyon 1).
Drug treatments
For the in vitro studies, vortioxetine (H. Lundbeck A/S, DK) was dissolved in DMSO; AS19 ((2S)-(þ)-5-(1,3,5-trimethylpyrazol-4-yl)-2-(dimethylamino)tetralin), a reported 5-HT 7 receptor partial agonist (Bonaventure et al., 2007; Roenneberg et al., 2008) , and SB269970 ((2R)-1-[(3-hydroxyphenyl)sulfonyl]-2-[2-(4-methyl-1-piperidinyl)ethyl]pyrrolidine hydrochloride), a potent 5-HT 7 receptor antagonist (Hagan et al., 2000) (Tocris Bioscience, Ellisville, MO) were dissolved in DMSO and sterile water, respectively; flesinoxan, a 5-HT 1A receptor agonist (synthesized by H. Lundbeck A/S, DK) was dissolved in saline. At the time of tissue treatment, drugs were diluted into the culture media to final concentrations. The concentrations of the working stock solutions were such that each treatment condition had the same final concentration of DMSO, which never exceeded 0.1% (v/v) .
For the wheel-running experiments, AS19 was dissolved in 20% 2-hydroxypropyl-b-cyclodextrin (SigmaeAldrich, St. Louis, MO), while flesinoxan, SB267790 and vortioxetine were dissolved in 10% 2-hydroxypropyl-b-cyclodextrin. Prior to administration, the pH was adjusted to pH 5e6 with 0.1 N NaOH. Drugs and vehicles were administered subcutaneously (s.c.) in a volume of 2 ml/kg body weight. All doses used are expressed as mg/kg of the base. Acute dosing occurred at the end of the light period, between Zeitgeber Time 11 and 12 (ZT11 and ZT12). Animals were switched from the prevailing 12:12 LD cycle to a period of constant darkness immediately after treatment, which coincided with the time of lights-off (ZT12). This method was employed to minimize light cues and thus allow the expression of endogenous rhythms. Animals were kept in constant darkness (DD) for approximately 10e14 days following acute drug administration. Dosing between ZT11 and ZT12 was chosen to mimic the early morning dose commonly used by patients and to be less disruptive to the normal sleepewake cycle of the rodents.
For the object recognition experiments, vortioxetine was dissolved in 10% 2-hydroxypropyl-b-cyclodextrin. AS19 was purchased from Tocris Bioscience (Illkirch, France) and dissolved in 0.5% methylcellulose. SB269970 was purchased from Sequoia Research Products Lt (Pangbourne, UK) and was dissolved in distilled water. Drugs and vehicles were administered intraperitoneally (i.p.). All doses used are expressed as mg/kg of the salt.
Tissue preparation
Tissue explants containing the SCN from PER2::LUC knock-in mice were prepared according to published methods (Yoo et al., 2004) . Briefly, animals were anesthetized with isoflurane, brains were rapidly removed and 300 mm coronal sections through the SCN were cut on a vibratome (Campden Instruments, Lafayette, IN) in chilled Hank's balanced salt solution (Invitrogen, Carlsbad, CA). Sections were trimmed by hand to include the SCN and a minimum of surrounding tissue and immediately transferred to culture inserts (Millipore, Billerica, MA) in 35 mm dishes (BD Falcon, Franklin Lakes, NJ). Dishes contained 1.2 ml Dulbecco's modified Eagle's medium (SigmaeAldrich, St. Louis, MO) supplemented with 1Â B27 (Invitrogen), 4 mM L glutamine (Invitrogen), 25 mM glucose (Sigma), 4.2 mM NaHCO 3 (Sigma), 10 mM HEPES (Sigma), 25 U/ml penicillin-G sodium (Invitrogen), 34 mM streptomycin sulfate (Invitrogen), and 100 mM beetle luciferin (Promega, Madison, WI, USA) and were sealed with vacuum grease (Dow, Midland, MI) and a glass coverslip. Two sections from SCN tissue were collected from a single animal; multiple samples of the same tissue from a single animal were placed in different treatment groups.
Bioluminescence monitoring
SCN tissue cultures were maintained at 35.8 C, and integrated bioluminescence was collected for 60 s every 10 min with a commercial luminometer (LumiCycle, Actimetrics, Wilmette, IL) before and after treatment. Bioluminescence analysis was performed using LumiCycle Analysis software. Data from the dissection day (Day 0) and from the days with media changes or day 1 of treatment were excluded from the analysis. All tissues were incubated in the aforementioned media for the first week to obtain a baseline, followed by control media or drug treatment once a week. Although the amplitude of the rhythms slightly damped towards the end of each week, media changes consistently reset the phase and amplitude of the cultures. Bioluminescence traces were de-trended by baseline subtraction of a 24 h moving average and then smoothed with a 2 h running average. De-trended and smoothed data were analyzed for periodicity with a c 2 periodogram (Lumicycle Analysis software; Actimetrics Inc., Evanston, IL). Chi-square tests for the period of Per2-luc expression were considered significant at p < 0.001. The period of the PER2::LUC expression rhythms was determined using the sine fit curve-fitting method; mean values obtained in the control (vehicle) groups ranged from 24.75 ± 0.07 to 24.83 ± 0.07 h (Figs. 1 and 2), in keeping with numerous published reports (Ehlen et al., 2001; Mullins et al., 1999; Yu and Weaver, 2011) . A minimum of 3 days of bioluminescence data was included in the analysis. Period values were compared using one-way analysis of variance (ANOVA) followed by a NewmaneKeuls multiple comparison test. All comparisons were considered significant at p < 0.05.
Locomotor activity rhythm monitoring
Daily wheel-running activity was monitored with Running Wheel Activity Software (AWM V12.0, Lafayette Instruments, Lafayette, IN) via activity wheel counters (Model 86061) interfaced with computers, prior to and following drug administration. Total revolutions of the activity wheel were continuously recorded in 2-min epochs. Collected data were split using AWM software to obtain interval count data for further analysis by Clocklab software (Actimetrics). Cumulative activity was represented in actograms, from which activity onsets and associated circadian parameters were calculated. Least-squares lines were fitted to the onsets of activity before and after dosing. The difference between the intersections of the two lines on the first day after treatment was used to calculate the shift in phase (by convention a minus (À) symbol indicates a delay and a positive (þ) symbol indicates an advance). Statistical analyses of the phase changes comprised an ANOVA followed by a NewmaneKeuls multiple comparison test. p < 0.05 was considered significant.
Object recognition test
The object recognition task was performed in a Plexiglas Y-maze apparatus (45 Â 15 Â 33 cm). It is based on the natural propensity of rats to explore novelty in their environment. More specifically, rodents are able to discriminate between a novel and a previously seen (i.e., familiar) object. The Y-maze was placed in a room illuminated only by a halogen lamp oriented towards the ceiling and giving a uniform dim light in the apparatus (intensity of 60 lux) (Bartolini et al., 1996; BertainaAnglade et al., 2011) . The Y-maze (floor and walls) and the objects were washed with ethanol 10% and dried thoroughly after each trial. The objects were different in shape, color and texture. They were made of glass (white) and metal (gray), around 14 cm high and too heavy to be displaced by rats. Each pair of objects was previously tested for absence of spontaneous preference for one member of the pair. In each experimental group, the role (familiar versus novel object) and the relative position of the two objects were counterbalanced and randomly permuted. Rats were placed in the experimental room for at least 30 min before testing.
The experiment consisted of 4 sessions. On days 1 and 2, rats received two habituation sessions to the area and test room environment: animals were allowed to freely explore the apparatus for 6 min per day. For the test session, rats were submitted to two trials with a 24 h inter-trial interval. During the first trial (day 3, learning trial, T1), animals were placed in the Y-maze containing 2 identical objects and left for 5 min to explore the objects. Any rat not exploring the objects for at least 8 s was excluded from the experiments. Exploration was defined as the animal having its head within 2 cm of the object while looking at, sniffing, or touching it. In the second trial (test trial, T2), which lasted 5 min, animals were exposed to an identical copy of one of the objects previously seen during the first trial and a novel object. Results were presented as time (sec) spent in active exploration of the familiar (F) or novel (N) object during T2 ± SEM. Recognition memory was estimated using a recognition index (RI): [(N À F)/(N þ F)] Â 100. Animals with low level of object exploration (novel þ familiar < 5 s) were excluded from the data analysis. The statistical analysis was undertaken using an ANOVA followed by NewmaneKeuls post hoc test; p < 0.05 was considered significant. Using a 24 h retention interval, we assessed the object memory performance of rats after acute administrations of vehicle, vortioxetine (10 mg/kg, i.p.), AS19 (5 mg/kg, i.p.) or SB269970 (4 mg/kg, i.p.) alone and combinations of vortioxetine and AS19 or SB269960 and AS19. Dosing occurred just after T1 and 1 h before T2.
Results
3.1. Effects of vortioxetine alone and in combination with AS19, a 5-HT 7 receptor ligand, on circadian rhythm regulation in SCN tissue explants from mPER2::LUC mice Incubation of SCN tissue explants from PER2::LUC mice with 0.1 mM vortioxetine significantly and reproducibly increased the period length (t) of PER2 bioluminescence (F(4,46) ¼ 7.228, p < 0.0001). Higher or lower vortioxetine concentrations had no significant effect on the period length (Fig. 1A) . Vortioxetine did not affect the amplitude of PER2 bioluminescence. Combining vortioxetine with the 5-HT 1A receptor agonist flesinoxan or the 5-HT 7 receptor antagonist SB269970 did not produce further changes (data not shown). When 0.1 mM vortioxetine was combined with the partial 5-HT 7 receptor agonist AS19 0.01 mM (an active concentration that shortens period length, Westrich et al., 2013) , the effect of vortioxetine was abolished (F(3,44) ¼ 10.38, p < 0.0001) and the period length of PER2 bioluminescence was not different from that of controls (Fig. 2) .
Effects of vortioxetine alone and in combination with AS19 on circadian rhythm regulation in wheel-running behavior
The acute effects of vortioxetine and AS19 (alone and in combination) on circadian rhythm regulation were studied in freely behaving rats with access to running wheels. A significant main effect of treatments was observed following the one-way ANOVA analysis (F(3,27) ¼ 11.33, p < 0.0001). Vortioxetine (10 mg/kg, s.c.) alone produced a significant phase delay (DF ¼ À0.82 ± 0.07 h, p < 0.001). AS19 (10 mg/kg, s.c.) administered alone at similar time points as vortioxetine produced no change in the occurence of activity onsets (DF ¼ À0.12 ± 0.08 h) compared to vehicle (DF ¼ À0.10 ± 0.14 h). When vortioxetine was combined with AS19 in paired injections, its effect on the circadian phase was markedly attenuated (DF ¼ À0.36 ± 0.10 h, p < 0.001) compared to vortioxetine alone (Fig. 3) .
Effects of vortioxetine alone and in combination with flesinoxan or SB269970 on circadian rhythm regulation in wheelrunning behavior
Receptor occupancy studies in rodents suggest that the 10 mg/ kg vortioxetine dose used in this study corresponds to approximately 90% SERT occupancy (Leiser et al., 2014) , which corresponds to the top end of the clinically relevant dose range (defined as 50e90% SERT occupancy; (Areberg et al., 2012; Stenkrona et al., 2013) ). However, direct translation of vortioxetine's pharmacological effects may be difficult from the perspective that vortioxetine has approximately 10 fold lower affinity at the rat 5-HT 1A and 5-HT 7 receptors compared to human receptors, in cellular in vitro assays (Bang-Andersen et al., 2011; Westrich et al., 2012) . In order to investigate whether the comparatively higher 5-HT 1A receptor activity expected in humans at a similar dose leads to any additional effects on circadian rhythm, the 5-HT 1A receptor selective agonist flesinoxan was co-administered with vortioxetine (Fig. 4) . Although flesinoxan alone did not affect the circadian phase, addition of flesinoxan (2.5 mg/kg s.c.) to vortioxetine produced a phase delay that was significantly different from vehicle (DF ¼ À0.85 ± 0.22 h, p < 0.05), but similar in magnitude to that of vortioxetine alone (DF ¼ À0.74 ± 0.13 h, F(3,12) ¼ 6.55, p < 0.05). Likewise, coadministration of vortioxetine (10 mg/kg, s.c.) and SB269970 (30 mg/kg, s.c.) produced a phase delay (data not shown) that was significantly different from vehicle (DF ¼ À0.72 ± 0.15 h, p < 0.05), but not from that of vortioxetine alone (DF ¼ À0.79 ± 0.16 h, F(3,12) ¼ 7.16, p < 0.05). SB269970 alone had no effect on the circadian phase (DF ¼ À0.28 ± 0.04 h, p > 0.05 versus vehicle).
Combined effects of flesinoxan and SB269970 on circadian rhythm regulation in wheel-running behavior
Based on the mechanisms of action that vortioxetine possesses, we also tested the effect of combining the 5-HT 1A receptor selective agonist flesinoxan (2.5 mg/kg, s.c.) and the 5-HT 7 receptor agonist SB269970 (30 mg/kg, s.c.). When each compound was administered alone to rats with access to running wheels at similar time points as vortioxetine, neither had an effect on the circadian phase (Fig. 5) ; however, their combination produced a robust and significant phase delay (DF ¼ À0.71 ± 0.11 h, F(3,12) ¼ 5.77, p < 0.05). The magnitude of this phase delay was slightly smaller, but similar to the average phase delay induced by vortioxetine alone in our experiments (DF ¼ À0.78 h).
Effects of vortioxetine alone and in combination with AS19 on recognition memory in the object recognition task
In the object recognition task (Fig. 7) , one-way ANOVA showed a significant main effect of treatments (F(5,54) ¼ 6.23, p < 0.001). While control rats spent no more time exploring the novel object than the familiar one (recognition index or RI ¼ 19.1 ± 4.3%; Fig. 7 ), vortioxetine (10 mg/kg, i.p.) increased the recognition index significantly compared to vehicle controls (RI ¼ 46.7 ± 4.5%; p < 0.001). Although AS19 (5 mg/kg, i.p.) alone increased the recognition index (RI ¼ 35.5 ± 4.4%; p < 0.05), the effect of vortioxetine was no longer present when vortioxetine was combined with AS19 (RI ¼ 12.4 ± 6.0%; p < 0.001 for vortioxetine þ AS19 versus vortioxetine alone). Similarly, the effect of AS19 was significantly prevented when combined with the selective 5-HT 7 receptor antagonist SB269970 (4 mg/kg, i.p.) (RI ¼ 14.1 ± 4.6%; p < 0.01 for SB269970 þ AS19 versus AS19 alone), which alone did not alter the recognition index compared to vehicle controls (RI ¼ 20.1 ± 6.3%; p > 0.05).
Discussion
In the present study, we showed that vortioxetine's modulation of 5-HT 7 receptors may play a role in its modulatory effects on circadian rhythms (in tissue culture and behaving rodents) and memory-improving effects on a time delay-induced deficit of recognition memory.
Vortioxetine increased the period length (t) of PER2 bioluminescence of SCN tissue explants from PER2::LUC mice and induced Fig. 3 . Vortioxetine (10 mg/kg, s.c.) produces significant changes in daily wheel-running behavior. Top: Representative double-plotted actograms showing a phase delay following acute administration of vortioxetine at ZT 11, and the lack of an effect on circadian phase when vortioxetine is co-administered with AS19 (10 mg/kg, s.c.) in paired injections. The shaded areas represent daily wheel-running activity under constant darkness conditions. Bottom: Vortioxetine produces a significant phase delay, which is absent when vortioxetine is combined with AS19 (mean ± SEM; *p < 0.0001 versus vehicle and AS19, <0.001 versus vortioxetine þ AS19; NewmaneKeuls post-hoc test; n ¼ 7e8 animals/group). a phase delay (i.e., later timing) in the rat circadian wheel-running rhythm when administered within 1 h of activity onset (before the beginning of the subjective night). The modulation of PER2 bioluminescence by vortioxetine was concentration-dependent ( Fig. 1) with an increase in period length observed only at 0.1 mM. This result was reproducible in experiments in which both higher and lower concentrations were used. The fact that vortioxetine acts through multiple 5-HT receptors, in addition to inhibiting the SERT (Mork et al., 2012; Westrich et al., 2012) , supports our results, which reflect a gradual engagement of receptors as vortioxetine concentration increases. Vortioxetine's regulation of circadian rhythms likely involves a complex interplay between 5-HT tone and inhibition/activation of 5-HT receptor subtypes, i.e., 5-HT 1A , 5-HT 1B , 5-HT 3 , and 5-HT 7 receptors (Graff et al., 2007; Lovenberg et al., 1993; Pickard et al., 1999; Roca et al., 1993) . This complex mechanism of action makes it difficult to assess the importance of contributions from the individual receptor subtypes. Various intricate and quite opposite interactions between different 5-HT receptors may be involved in the observed effects of vortioxetine on circadian rhythms. Thus, vortioxetine yields different effects at different concentrations. AS19, described as 5-HT 7 receptor partial agonist with a 77% intrinsic efficacy (Bosker et al., 2009; Vela Hernandez et al., 2008) shortened the period length as previously shown (Westrich et al., 2013) . When combined with vortioxetine 0.1 mM, AS19 abolishes the period lengthening induced by vortioxetine alone (Fig. 2) , suggesting that vortioxetine's effects on PER2 bioluminescence may be mediated through the 5-HT 7 receptor at this particular ex vivo concentration.
Rats exposed to an acute dose of vortioxetine (10 mg/kg, s.c.) display a shift (phase delay, i.e., delayed timing) in their circadian rhythm. However, when AS19 is co-administered with vortioxetine, the change induced by vortioxetine alone in the circadian phase is abolished (Fig. 3) . Even though AS19 alone does not induce a phase advance, as hypothesized based on our ex-vivo results (Fig. 2) and work of other colleagues (Adriani et al., 2012; Sprouse et al., 2004) , the present findings are consistent with the fact that activation of 5-HT 7 receptors in the presence of AS19 opposes the phase delay induced by vortioxetine alone.
The vortioxetine dose of 10 mg/kg was chosen because it produces a similar level of SERT occupancy (~90%) in rodents as the highest clinically used dose, 20 mg/day (Areberg et al., 2012; Stenkrona et al., 2013) . Ex vivo binding studies in rats indicate that an acute vortioxetine dose of 10 mg/kg, s.c. corresponds to more than 80% occupancy of 5-HT 3 and 5-HT 1B receptors and SERT and approximately 35e40% occupancy of 5-HT 1A and 5-HT 7 receptors (Leiser et al., 2014) . Moreover, since vortioxetine has approximately 10 fold lower affinity at the rat 5-HT 1A and 5-HT 7 receptors compared to humans (Bang-Andersen et al., 2011; Westrich et al., 2012) , we co-administered vortioxetine with flesinoxan (Fig. 4) or SB269970 (data not shown). Although flesinoxan and SB269970 alone had no effect on the circadian phase, their combination produced a robust phase delay (Fig. 5 ) equivalent in magnitude (mean D4 ¼ À0.71 h) to that induced by vortioxetine (mean D4 ¼ À0.78 h) alone. This observation could suggest that a relatively low level of 5-HT 1A and 5-HT 7 receptor occupancy is required for these targets to produce a maximum response on Fig. 4 . Vortioxetine alone (10 mg/kg, s.c.) and in combination with flesinoxan (2.5 mg/kg, s.c.) produces significant changes in daily wheel-running behavior. Top: Representative double-plotted actograms showing a phase delay following acute administration of vortioxetine alone and in combination with flesinoxan at ZT 11. The shaded areas represent daily wheel-running activity under constant darkness conditions. Bottom: Vortioxetine alone and in combination with flesinoxan produces a significant phase delay (mean ± SEM; *p < 0.05 versus vehicle and all other treatment groups; NewmaneKeuls post-hoc test; n ¼ 4 animals/group). circadian regulation. This hypothesis would also be compatible with the observation that the active flesinoxan dose in the present study (2.5 mg/kg, s.c.) corresponds to approximately the same level of 5-HT 1A receptor occupancy (30e40%) reported by Leiser et al. (2014) and probably a low 5-HT 7 receptor occupancy with SB269970 (Westrich et al., 2013) due to its poor bloodebrain barrier penetration. However, SB269970 administered with an ineffective dose of escitalopram, did produce a shift in the circadian phase (Fig. 6 e reproduced with permission from Westrich et al. (2013) ).
The fact that escitalopram alone does not affect circadian rhythm (Westrich et al., 2013) , while vortioxetine does, must be ascribed to its multimodal action involving inhibition of the SERT and direct effects at 5-HT receptors, in particular 5-HT 1A , 5-HT 1B and 5-HT 7 receptors, all 3 of which have been implicated in the control of circadian rhythms (Graff et al., 2007; Lovenberg et al., 1993; Pickard et al., 1999; Roca et al., 1993) . Thus, several lines of evidence support the hypothesis that 5-HT tone together with activation/blockade of several 5-HT receptors can modulate circadian rhythms, while blockade of the SERT (i.e., increase in 5-HT tone) may not be sufficient to cause a measurable effect.
Taken together, our data consistently show that the effect of vortioxetine in modulating PER2 bioluminescence and wheelrunning behavior is abolished in the presence of AS19. This indicates a strong involvement of 5-HT 7 receptors in vortioxetine's effects on circadian rhythms. Since poor circadian synchrony has been linked to maladaptive changes in unipolar and bipolar depression (Wirz-Justice, 2003 , 2006 , antidepressants that target key 5-HT receptor subtypes involved in circadian rhythm regulation may have therapeutic utility. The putative impact of this property of vortioxetine remains to be studied. The melatonin receptor agonist and 5-HT 2C receptor antagonist agomelatine (Tardito et al., 2012 ) is thought to exert its antidepressant activity, at least in part, through regulation of circadian rhythms (Lanfumey et al., 2013) . Whereas vortioxetine likely affects mood and circadian rhythms via different mechanisms than agomelatine, they may overlap in their ability to restore the proper phase alignment between the SCN pacemaker and the lightedark cycle (Dallaspezia and Benedetti, 2011; Duncan, 1996; Healy and Waterhouse, 1995; Wirz-Justice, 2003 , 2006 , which is potentially disrupted during a depressive episode. But a recent clinical study in which MDD patients with an inadequate response to SSRI/SNRI monotherapy were randomized to flexible-dose treatment with vortioxetine (10e20 mg/day) or agomelatine (25e50 mg/day) showed that vortioxetine was statistically superior to agomelatine on the predefined primary outcome using the Montgomery-Åsberg Depression Rating Scale (MADRS) (H€ aggstr€ om et al., 2013) .
As seen with the pro-cognitive agent donepezil, vortioxetine has been shown to increase the time that rats spend investigating the novel object in the 24-h object recognition test . Using the same retention interval, the present study confirms that acute administration of vortioxetine (10 mg/kg, i.p.) improved object memory performance of naïve rats. Our data indicate that 5-HT 7 receptor modulation may be involved in vortioxetine's cognitive enhancing properties, since the partial 5-HT 7 receptor agonist, AS19, attenuated the memory enhancing properties of vortioxetine in the object recognition task. Intriguingly, AS19 alone also exerts a memory enhancing effect in the object recognition task. Since AS19 is a potent (subnanomolar in vitro potency) and selective 5-HT 7 receptor agonist (Di Pilato et al., 2014) , its effects on memory are likely mediated by 5-HT 7 receptors. This is indeed confirmed by the fact that the 5-HT 7 receptor antagonist SB269970 prevented the enhancing effect of AS19 in the object recognition task. However, the literature is still confusing since both 5-HT 7 receptor agonists (e.g., AS19) and 5-HT 7 receptor antagonists (e.g., SB269970) have been reported to have memory enhancing or memory impairing properties depending on the animal model and test conditions (such as the 5-HT tone) (Gasbarri and Pompili, 2014; Meneses, 2014) . Also, a phase-dependent involvement of 5-HT 7 receptors has been proposed for which the acquisition phase requires a silencing of 5-HT 7 receptors while the consolidation phase requires a high activation of 5-HT 7 receptors (Freret et al., 2014) . Similar to the coupling of 5-HT 1A and 5-HT 7 receptors in the regulation of circadian rhythms, a study by Eriksson et al. (2012) reported a complex, brain region dependent crosstalk between 5-HT 1A and 5-HT 7 receptors in the regulation of memory function (also see the review by Meneses, 2014) . Thus, while the 5-HT 1A and 5-HT 7 receptor agonist 8-OH-DPAT impaired memory function in a passive avoidance learning test, co-administration of 8-OH-DPAT and the 5-HT 1A receptor antagonist NAD-299 facilitated memory (Eriksson et al., 2012) . The authors emphasized that since 5-HT has high affinity for both 5-HT 1A and 5-HT 7 receptors compared to other 5-HT The acute administration of vortioxetine (10 mg/kg, i.p.) significantly increased the time exploring the novel object compared to the familiar one (mean ± SEM; **p < 0.01). Interestingly, the 5-HT 7 receptor partial agonist AS19 (5 mg/kg, i.p.) alone enhanced the recognition index, but significantly prevented the increase in the recognition index induced by vortioxetine (mean ± SEM; ###p < 0.001). The acute administration of selective 5-HT 7 receptor antagonist SB269970 (4 mg/kg, i.p.) did not affect the time spent exploring the novel object compared to the familiar one (p > 0.05), but significantly prevented the increase in the recognition index induced by AS19 (mean ± SEM; ##p < 0.01; NewmaneKeuls post-hoc test; n ¼ 8e12 animals/group).
receptors, a change in signaling through one them would be likely to affect the function of the other (Eriksson et al., 2012) . As vortioxetine is a 5-HT 7 receptor antagonist and a 5-HT 1A receptor agonist (Mork et al., 2012) and vortioxetine at the dose tested occupies 5-HT 1A as well as 5-HT 7 receptors, it can be hypothesized that AS19 interferes negatively with the complex interaction of vortioxetine at 5-HT 1A and 5-HT 7 receptors through its interaction at 5-HT 7 receptors.
A limitation of our studies relates to the fact that vortioxetine acts through multiple interdependent targets, which implies that determination of the precise function at each of its individual targets is extremely difficult. Furthermore, target-specific potency differences between rodents and human offers another layer of complexity to our studies. As aforementioned, the in vitro affinity of vortioxetine for rat 5-HT 1A and 5-HT 7 receptors is approximately 10-fold lower compared to the human receptors. In order to avoid underestimating the effects of vortioxetine at these receptors, we co-administered it with the 5-HT 1A receptor agonist flesinoxan or the 5-HT 7 receptor antagonist SB269970. However, this approach is only an approximation, since there are no available methods to assess vortioxetine's occupancy at the 5-HT 1A and 5-HT 7 receptors in the human brain. Taken together, the engagement of multiple targets and the species differences add to the complexity and interpretation of our research. To complement our pharmacological studies, a future direction could be to study the effects of vortioxetine in genetically engineered mice with induced mutations, such as knockout of a functional target, or expression of a human target (e.g. 5-HT 1A receptors). However, the ultimate understanding of vortioxetine's effects on circadian rhythms and cognitive function must come from clinical studies in humans.
Conclusion
Vortioxetine has the potential to modulate circadian rhythms by prolonging the period length and producing a phase delay. In line with published preclinical and clinical data vortioxetine has the potential to positively affect memory function. Finally, the study indicates that 5-HT 7 receptors may be involved in these significant effects on circadian rhythm and recognition memory in rodents. The potential clinical implications of these preclinical findings remain to be explored.
